Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
The study marks victory against Soliris, but Apellis could still find the market hard to crack.
After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.
A week after UCB bought Ra to get hold of its complement inhibitor, Alexion takes out Achillion for much the same reason.
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.
Others hoping to get FDA approvals include Sage Therapeutics and Novartis, but hopes look dimmer for Lexicon and Sanofi.
Promising mid-stage data in a third indication for efgartigimod have given the Belgian company another boost.